(NASDAQ: PAHC) Phibro Animal Health's forecast annual revenue growth rate of 0.37% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 1.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.03%.
Phibro Animal Health's revenue in 2023 is $960,117,000.On average, 1 Wall Street analysts forecast PAHC's revenue for 2023 to be $39,356,140,785, with the lowest PAHC revenue forecast at $39,356,140,785, and the highest PAHC revenue forecast at $39,356,140,785. On average, 1 Wall Street analysts forecast PAHC's revenue for 2024 to be $40,779,842,607, with the lowest PAHC revenue forecast at $40,779,842,607, and the highest PAHC revenue forecast at $40,779,842,607.
In 2025, PAHC is forecast to generate $37,384,830,184 in revenue, with the lowest revenue forecast at $37,384,830,184 and the highest revenue forecast at $37,384,830,184.